Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms BET PROTAC(Boehringer Ingelheim/University of Dundee), Proteolysis targeting chimeric molecules(Boehringer Ingelheim/University of Dundee), SMARC2 protein degader(Boehringer Ingelheim/University of Dundee) + [1] |
Target |
Mechanism BRD4 degraders(Bromodomain-containing protein 4 degraders), Proteolysis |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC49H60ClN9O8S2 |
InChIKeyPTAMRJLIOCHJMQ-PYNGZGNASA-N |
CAS Registry1797406-69-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 16 Jun 2015 |